Mr. Chairman, I thank the full committee chairman, Mr. Goodlatte, for supporting the REVIEW Act as an original cosponsor and for moving it through the Judiciary Committee. I am also grateful for the many other Members who have cosponsored this bill. The REVIEW Act rests upon a very simple premise: that regulations with annual costs exceeding $1 billion annually should receive full judicial review before they go into effect. The regulations we are concerned about are so massive that their compliance costs are felt nationwide. These regulations touch every corner of our economy. They drive up the cost to put food on the table and clothes on our backs, and, in the worst of situations, they take away the very jobs Americans have earned. Due to these immense costs, it is not only prudent, but appropriate that aggrieved parties have their day in court. These costs demand that executive agencies must justify their reasoning and legal underpinnings of their rulemaking. Requiring American taxpayers and businesses to comply before the judicial process runs its course reeks of injustice. Historically, these high-impact rules with costs over $1 billion annually have been few and far between. Since 2006, there have been just 26 in total. However, in recent years, their number has grown exponentially alongside the growth and reach of the regulatory state. There have been an average of three over the past 8 years and six in 2014 alone.…
Share & report
More from Tom Marino
Every project is going to create jobs, and the good part about the Permit Litigation Efficiency Act that you are considering today is that in the history of the United States, until FAST-41 when a court was looking to impose an injunction…
Mr. Speaker, I was unable to attend votes on April 28, 2017, due to a family medical issue. Had I been present, I would have voted as follows: ``Yea'' for rollcall vote 235. ``Yea'' for rollcall vote 236. ____________________
Hills & Company Letter submitted by the Honorable Tom Marino, Pennsylvania, Chairman, Subcommittee on Regulatory Reform, Commercial and Antitrust Law, Committee on the Judiciary.
I look forward to hearing the witnesses' views on these issues and whether our existing antitrust laws are equipped to address these antitrust concerns in the FDA approval process.





